Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 805 results for "alexion pharmaceuticals"

Alexion Pharmaceuticals (ALXN) Showing Bearish Technicals With...

( via COMTEX) -- Alexion Pharmaceuticals Inc ( ALXN ) was selected by MarketIntelligenceCenter.comaEUR(TM)s trade-picking algorithms today after trading between $157.44 and $162.45 on Monday before closing at $159.59. A ..., 9 hours ago

19 images for alexion pharmaceuticals

American Banking News, 2 weeks ago
Wall Street Pit, 1 week ago
Wall Street Pit, 1 week ago
Wall Street Pit, 1 week ago
Wall Street Pit, 1 week ago
Wall Street Pit, 1 week ago
Jutia Group, 2 weeks ago
State Of The, 1 week ago
Jutia Group, 4 weeks ago, 1 week ago

Riassunto: I pazienti pediatrici affetti da ipofosfatasia trattati col farmaco sperimentale asfotase alfa hanno mostrato miglioramenti nella crescita e nelle funzionalità fisiche

DUBLINO, Irlanda--( BUSINESS WIRE )--Alexion Pharmaceuticals ha oggi annunciato che alcuni ricercatori hanno presentato i dati di estensioni dello studio di fase 2 in aperto su asfotase alfa, una terapia enzimatico-sostitutiva (ERT) ...
 Business Wire4 days ago Anhaltende Verbesserungen der körperlichen Funktion und des Wachstums bei pädiatrischen Patienten mit Hypophosphatasie nach der Therapie mit dem Prüfpräparat Asfotase Alfa  Business Wire4 days ago Les patients pédiatriques atteints d'hypophosphatasie et recevant de l'Asfotase Alfa expérimentale ont constaté des améliorations constantes de la croissance et de la fonction physique  Business Wire4 days ago Alexion Pharmaceuticals : Asfotase Alfa Secures Orphan Drug Designation in Japan  4 Traders3 days ago

Execs move up at Alexion

News Editor Alexion Pharmaceuticals (NASDAQ:ALXN) promotes key executives. EVP and Chief Commercial Officer David Hallal promoted to COO. SVP and Chief HR Officer Clare Carmichael promoted to EVP and CHRO. SVP and General Counsel John ...
 Seeking Alpha6 days ago Alexion Names David Hallal COO - Quick Facts  RTTNews.com6 days ago Stock Investors Sell Off Shares of Alexion Pharmaceuticals, Down 2.9%  Individual.com1 week ago Alexion Pharmaceuticals Shares Sinking Lower, Down 1.5%  Individual.com1 week ago

Resumen: Los pacientes pediátricos con hipofosfatasia que han recibido asfotasa alfa experimental han registrado mejoras constantes en la función física y crecimiento

DUBLÍN, Irlanda--( BUSINESS WIRE )--Alexion Pharmaceuticals ha comunicado que los investigadores han presentados datos de las fases de prolongación abiertas de dos estudios de fase 2 de la asfotasa alfa, un tratamiento en fase de ...
 Business Wire4 days ago Resumen: Se ha observado una mejora en la supervivencia de los pacientes pediátricos con hipofosfatasia grave (HPP) que han sido tratados con el fármaco en fase de investigación Asfotase Alfa durante cinco años  Business Wire1 week ago

Alexion Pharmaceuticals Falls 1.41% on Heavy Volume: Watch For Potential Rebound

Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $157.30 to a high of $162.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $161.00 on volume of 1.1 million ...
 Individual.com1 week ago SmarTrend Watching for Potential Rebound in Shares of Alexion Pharmaceuticals After 1.70% Loss  Individual.com2 weeks ago Alexion Pharmaceuticals Falls 2.54% on Heavy Volume: Watch For Potential Rebound  Individual.com2 weeks ago

Alexion announces encouraging data from hypophosphatasia analysis

Alexion Pharmaceuticals, Inc. has announced encouraging data from an integrated analysis of survival from two open-label, Phase II studies of asfotase alfa in pediatric patients with hypophosphatasia, or HPP, compared with data from a retrospective ...
 Individual.com6 days ago Alexion report new data from two open-label, Phase II studies of asfotase alfa in pediatric patients  Pharmaceutical Business Review6 days ago

ALEXION PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits

(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mr. David Hallal has been named Chief ...
 TMC Net6 days ago

Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise?

By Stephen Simpson, CFA: As great as Alexion (NASDAQ:ALXN) has shown itself to be with its orphan drug Soliris for rare kidney ailments, Intercept Pharmaceuticals (NASDAQ:ICPT) may be establishing a similar path in the until-recently overlooked ...
 Austin American Statesman1 week ago

NICE Suggests Commissioning of Eculizumab for Patients with aHUS

Alexion Pharmaceuticals reported that the National Institute for Health and Clinical Excellence Highly Specialised Technologies Evaluation Committee has reaffirmed the clinical value of eculizumab for the treatment of atypical hemolytic uremic ...
 Individual.com1 week ago ALEXION PHARMACEUTICALS : NICE Suggests Commissioning of Eculizumab for Patients with aHUS  4 Traders1 week ago

Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status

Alexion Pharmaceuticals ( ALXN ) announced that its primary pipeline candidate asfotase alfa has been granted Orphan Drug status in Japan for treating patients suffering from hypophosphatasia, a rare genetic disorder. The orphan drug designation, ...
 Yahoo! Finance2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less